Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy for malignant gliomas.

Christine Marosi1

  • 1Division of Medical Oncology, Department of Internal Medicine I, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. christine.marosi@meduniwien.ac.at

Wiener Medizinische Wochenschrift (1946)
|September 1, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glioblastoma radiomics can delineate systemic immune activity states like blood abundance of T cell populations or transcription factors.

Journal of neuroinflammation·2026
Same author

Age and sex as risk factors for health-related quality of life outcomes in patients with glioma: a CODAGLIO 2.0 analysis.

The oncologist·2026
Same author

The Presence of Neutrophil Extracellular Traps (NETs) in Brain Tumor Vessels Is Linked to Platelet Aggregates and Podoplanin in the Tumor Microenvironment.

Cancers·2025
Same author

Prognostic factors for overall survival in elderly patients with glioblastoma: Analysis of the pooled NOA-08 and Nordic trials with the CCTG-EORTC (CE.6) trial.

Neuro-oncology advances·2025
Same author

Towards integrating imaging and immunology in glioblastoma: mapping blood immune system metrics to tumor magnetic resonance image data.

Acta neuropathologica communications·2024
Same author

Well-intentioned is not always beneficial: Why we should question prescription habits.

Neuro-oncology practice·2024
Same journal

Necrotizing fasciitis of the thigh-a devastating sign of intestinal perforation.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Regenerative therapies in rehabilitation with interfaces with occupational medicine, geriatrics, and oncology: the example of extracorporeal shock wave therapy.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Cerebral toxoplasmosis in patients with peripheral B-cell lymphoma : A case series and a literature review.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Post-pandemic rebound of rotavirus and adenovirus in pediatric gastroenteritis: a 6-year antigen-based surveillance study from Turkey.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

Neuroaxis involvement in Chikungunya virus infection: a retrospective case series.

Wiener medizinische Wochenschrift (1946)·2026
Same journal

A complicated case of a spinal Scedosporium apiospermum infection with a favorable outcome-case report.

Wiener medizinische Wochenschrift (1946)·2026
See all related articles

Temozolomide, an oral alkylating agent, significantly improved survival for glioblastoma patients. This treatment is well-tolerated, maintaining patient quality of life with manageable side effects.

Area of Science:

  • Neuro-oncology
  • Clinical Oncology
  • Pharmacology

Background:

  • Glioblastoma multiforme has seen limited therapeutic advancements for over three decades.
  • Temozolomide is an oral alkylating agent used in cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of Temozolomide in newly diagnosed glioblastoma multiforme patients.
  • To assess the impact of Temozolomide on patient survival and quality of life.

Main Methods:

  • The study involved concomitant and adjuvant treatment with Temozolomide.
  • Weekly clinical and laboratory monitoring was implemented during the concomitant phase.
  • Prophylaxis against Pneumocystis carinii pneumonia was mandatory in the EORTC study.

Related Experiment Videos

Main Results:

  • Temozolomide significantly improved survival rates in patients with newly diagnosed glioblastoma multiforme.
  • The therapy was generally well-tolerated, with primarily hematological toxicities (thrombocytopenia, lymphocytopenia) in approximately 5% of patients.
  • Patient quality of life was maintained throughout the treatment duration.

Conclusions:

  • Concomitant and adjuvant Temozolomide represents a significant advancement in glioblastoma treatment, improving survival and quality of life.
  • Further research is warranted to explore Temozolomide's applicability to other brain tumors and optimize treatment schedules or combinations with biological agents.